Efficacy and safety of ocrelizumab in relapsing multiple sclerosis—results of the phase III double-blind, interferon beta-1a controlled OPERA I and II studies - Hauser, S L; Comi, G C; Hartung, H P
Presented at: 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis; October 9, 2015; Barcelona, Spain